Congratulations to ALX Oncology on the appointment of Alan Sandler, MD as Chief Medical Officer! Our best wishes to ALX for the establishment of evorpacept as a best-in-class, combinable therapeutic across multiple cancer indications. https://lnkd.in/gF_NSRcb
We are pleased to welcome Alan Sandler, MD, to our executive leadership team as Chief Medical Officer. “Dr. Sandler’s breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives. He is the ideal leader to advance the clinical development of evorpacept, our investigational lead compound, into late-stage clinical trials. We are thrilled to have him join our accomplished leadership team as we look towards 2025, which will be a transformational year for the company.” - Jason Lettmann, CEO of ALX Oncology Read more about Alan here: https://bit.ly/4frf98a